Chelariu-Raicu A - Search Results

1

Mahdi H, Chelariu-Raicu A, Slomovitz BM. Mahdi H, et al. Among authors: chelariu raicu a. Int J Gynecol Cancer. 2023 Mar 6;33(3):351-357. doi: 10.1136/ijgc-2022-003675. Int J Gynecol Cancer. 2023. PMID: 36878570 Free PMC article. Review.

2

Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.

Xiong C, Wen Y, Zhao J, Yin D, Xu L, Chelariu-Raicu A, Yao C, Leng X, Liu J, Chaudhari RR, Zhang S, Sood AK, Li C. Xiong C, et al. Sci Rep. 2020 Jan 16;10(1):520. doi: 10.1038/s41598-020-57477-x. Sci Rep. 2020. PMID: 31949258 Free PMC article.

3

Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype.

Chelariu-Raicu A, Wilke C, Brand M, Starzinski-Powitz A, Kiesel L, Schüring AN, Götte M. Chelariu-Raicu A, et al. Fertil Steril. 2016 Aug;106(2):378-85. doi: 10.1016/j.fertnstert.2016.03.032. Epub 2016 Mar 31. Fertil Steril. 2016. PMID: 27041028 Free article.

4

Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.

LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. LaFargue CJ, et al. Gynecol Oncol. 2022 Apr;165(1):82-89. doi: 10.1016/j.ygyno.2022.02.006. Epub 2022 Feb 23. Gynecol Oncol. 2022. PMID: 35216808 Free PMC article.

5

The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers.

Chelariu-Raicu A, Zibetti Dal Molin G, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2020 Oct;30(10):1608-1618. doi: 10.1136/ijgc-2020-001789. Epub 2020 Sep 14. Int J Gynecol Cancer. 2020. PMID: 32928926 Review.

6

Phase 2 study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer.

Slomovitz BM, Chelariu-Raicu A, Schmeler KM, Lu KH, Gershenson DM, Wolf J, Coleman RL. Slomovitz BM, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1733-1737. doi: 10.1136/ijgc-2020-001859. Epub 2020 Oct 5. Int J Gynecol Cancer. 2020. PMID: 33020204 Clinical Trial.

7

Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.

Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2020 Nov;30(11):1768-1774. doi: 10.1136/ijgc-2020-001863. Epub 2020 Oct 9. Int J Gynecol Cancer. 2020. PMID: 33037105 Clinical Trial.

8

Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer.

Chelariu-Raicu A, Mahdi H, Slomovitz BM. Chelariu-Raicu A, et al. Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):28-35. doi: 10.1097/GCO.0000000000000768. Curr Opin Obstet Gynecol. 2022. PMID: 34967812 Review.

9

Integrating antibody drug conjugates in the management of gynecologic cancers.

Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL. Chelariu-Raicu A, et al. Int J Gynecol Cancer. 2023 Mar 6;33(3):420-429. doi: 10.1136/ijgc-2022-003701. Int J Gynecol Cancer. 2023. PMID: 36878560 Review.

10

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.

Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Kim MS, et al. Mol Cancer Ther. 2020 Nov;19(11):2396-2406. doi: 10.1158/1535-7163.MCT-20-0030. Epub 2020 Sep 17. Mol Cancer Ther. 2020. PMID: 32943548 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters